BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. The company’s CEO Amir Reichman, as an international subject matter expert on pharmaceutical manufacturing and supply chains, has been consulted by members of U.S. Congress about related topics of interest. In 2021, Reichman participated in meetings in Washington, D.C., and earlier this year BiondVax welcomed a congressional delegation to its offices and GMP biologics manufacturing facility in Jerusalem. A Times of Israel article explains details about Congress’s interest in near-shoring the U.S. medical supply chain. The publication notes that during their visit to Israel, the Congresspeople, “met with then-prime minister Naftali Bennett, opposition leader and now presumptive incoming premier Benjamin Netanyahu, Defense Minister Benny Gantz, and U.S. Ambassador Tom Nides, as well as Amir Reichman, CEO of the Jerusalem-based BiondVax Pharmaceuticals.”
To view the full article, visit https://ibn.fm/yJkIz
About BiondVax Pharmaceuticals Ltd.
BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven country, 12,400 participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.